Mediclinic International plc Directorate Change (2678U)

TIDMMDC

RNS Number : 2678U

Mediclinic International plc

22 November 2019

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

22 November 2019

DIRECTORATE CHANGE

DR EDWIN HERTZOG TO RETIRE AS CO DEPUTY CHAIRMAN AND NON-EXECUTIVE DIRECTOR OF REMGRO

The Company announces that Dr Edwin Hertzog will retire as co deputy Chairman and non-executive director of Remgro Limited ("Remgro", Mediclinic's principal shareholder), with effect from the close of Remgro's Annual General Meeting, scheduled to be held on 28 November 2019.

As previously announced by Mediclinic on 24 July 2019, Dr Hertzog will retire as Chairman of the Group at the conclusion of the Company's 2020 Annual General meeting. A search for Dr Hertzog's successor as Chairman has been initiated and the Board will provide an update when appropriate.

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

Mediclinic comprises 77 hospitals, five sub-acute hospitals, 13 day case clinics and 22 outpatient clinics. Hirslanden operates 17 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations include 53 hospitals (three of which in Namibia), five sub-acute hospitals and nine day case clinics (four of which are operated by Intercare) across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operates seven hospitals, two day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Caroline Emmet

[phone]

Investor queries

James Arnold, Head of Investor Relations, Mediclinic International plc

[phone]

[e-mail]

Media queries

FTI Consulting

Brett Pollard/Ciara Martin - United Kingdom

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE Ltd sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAPGGUGGUPBGAG

(END) Dow Jones Newswires

November 22, 2019 02:00 ET (07:00 GMT)